Mizuho raises Xylem stock price target to $140 on efficiency gains

Published 12/09/2025, 12:22
Mizuho raises Xylem stock price target to $140 on efficiency gains

Investing.com - Mizuho raised its price target on Xylem (NYSE:XYL) to $140.00 from $125.00 on Friday, while maintaining a Neutral rating on the water technology company’s stock. The stock currently trades at $141.80, near its 52-week high of $145.33, with analyst targets ranging from $125 to $175.

The price target increase follows Mizuho’s comprehensive analysis of Xylem’s restructuring efforts and progress on its 80/20 initiatives, which the firm described as its most thorough examination of the stock since relaunching coverage in 2021. According to InvestingPro, 15 analysts have recently revised their earnings estimates upward for the upcoming period, suggesting growing confidence in the company’s strategy.

Mizuho cited "80/20 efforts, simplification momentum and rising peer multiples" as key factors collectively driving the higher valuation target for the water technology provider.

The research firm reiterated its 2025 earnings per share estimate of $4.77 for Xylem while adjusting its 2026 EPS forecast upward to $5.20 from its previous estimate of $5.15.

Mizuho’s report included benchmarking analysis examining Xylem’s efficiency, growth potential and profit margins as part of its evaluation of the company’s performance and outlook.

In other recent news, Xylem Inc. has reported financial results for the second quarter of 2025 that exceeded analysts’ expectations. The company posted earnings per share of $1.26, which was $0.11 higher than projected. Revenue also surpassed forecasts, reaching $2.3 billion compared to the anticipated $2.21 billion. These results highlight the company’s strong performance in the quarter. Furthermore, TD Cowen has adjusted its price target for Xylem’s stock, raising it from $125 to $130, while maintaining a Hold rating. The firm cited Xylem’s strong position in a crucial market, although it noted that future order comparisons might present challenges. These recent developments reflect Xylem’s robust financial health and market positioning.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.